iqvia holdings inc. - IQV

IQV

Close Chg Chg %
172.40 0.85 0.49%

Closed Market

173.25

+0.85 (0.49%)

Volume: 794.29K

Last Updated:

Apr 2, 2026, 3:59 PM EDT

Company Overview: iqvia holdings inc. - IQV

IQV Key Data

Open

$171.52

Day Range

169.79 - 177.12

52 Week Range

134.65 - 247.05

Market Cap

$29.40B

Shares Outstanding

169.70M

Public Float

168.07M

Beta

1.39

Rev. Per Employee

N/A

P/E Ratio

22.10

EPS

$7.93

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.53M

 

IQV Performance

1 Week
 
5.74%
 
1 Month
 
-0.70%
 
3 Months
 
-23.12%
 
1 Year
 
11.98%
 
5 Years
 
-12.52%
 

IQV Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 26
Full Ratings ➔

About iqvia holdings inc. - IQV

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

IQV At a Glance

IQVIA Holdings, Inc.
2400 Ellis Road
Durham, North Carolina 27703
Phone 1-919-998-2000 Revenue 16.30B
Industry Biotechnology Net Income 1.36B
Sector Health Technology 2025 Sales Growth 5.836%
Fiscal Year-end 12 / 2026 Employees 93,000
View SEC Filings

IQV Valuation

P/E Current 22.103
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 28.756
Price to Sales Ratio 2.399
Price to Book Ratio 5.879
Price to Cash Flow Ratio 14.74
Enterprise Value to EBITDA 15.578
Enterprise Value to Sales 3.272
Total Debt to Enterprise Value 0.305

IQV Efficiency

Revenue/Employee 175,311.828
Income Per Employee 14,623.656
Receivables Turnover 4.758
Total Asset Turnover 0.574

IQV Liquidity

Current Ratio 0.749
Quick Ratio 0.749
Cash Ratio 0.257

IQV Profitability

Gross Margin 26.251
Operating Margin 13.99
Pretax Margin 9.758
Net Margin 8.342
Return on Assets 4.785
Return on Equity 21.639
Return on Total Capital 5.975
Return on Invested Capital 6.78

IQV Capital Structure

Total Debt to Total Equity 250.038
Total Debt to Total Capital 71.432
Total Debt to Total Assets 54.301
Long-Term Debt to Equity 220.221
Long-Term Debt to Total Capital 62.913
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Iqvia Holdings Inc. - IQV

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
14.42B 14.96B 15.40B 16.30B
Sales Growth
+3.90% +3.77% +2.95% +5.84%
Cost of Goods Sold (COGS) incl D&A
10.51B 10.87B 11.14B 12.02B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.13B 1.13B 1.11B 1.14B
Depreciation
160.00M 151.00M 149.00M 160.00M
Amortization of Intangibles
970.00M 974.00M 965.00M 984.00M
COGS Growth
+0.14% +3.41% +2.52% +7.90%
Gross Income
3.91B 4.09B 4.26B 4.28B
Gross Income Growth
+15.55% +4.73% +4.10% +0.45%
Gross Profit Margin
+27.10% +27.35% +27.66% +26.25%
2022 2023 2024 2025 5-year trend
SG&A Expense
2.07B 2.05B 1.99B 2.00B
Research & Development
- - - -
-
Other SG&A
2.07B 2.05B 1.99B 2.00B
SGA Growth
+5.45% -0.87% -2.97% +0.35%
Other Operating Expense
- - - -
-
Unusual Expense
13.00M 32.00M (4.00M) 77.00M
EBIT after Unusual Expense
1.82B 2.01B 2.27B 2.20B
Non Operating Income/Expense
(67.00M) 170.00M 107.00M 120.00M
Non-Operating Interest Income
13.00M 36.00M 47.00M 45.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
394.00M 719.00M 711.00M 733.00M
Interest Expense Growth
+11.30% +82.49% -1.11% +3.09%
Gross Interest Expense
394.00M 719.00M 711.00M 733.00M
Interest Capitalized
- - - -
-
Pretax Income
1.36B 1.46B 1.67B 1.59B
Pretax Income Growth
+20.83% +7.04% +14.39% -4.67%
Pretax Margin
+9.45% +9.75% +10.83% +9.76%
Income Tax
260.00M 101.00M 301.00M 252.00M
Income Tax - Current - Domestic
24.00M 21.00M 44.00M 49.00M
Income Tax - Current - Foreign
358.00M 349.00M 386.00M 383.00M
Income Tax - Deferred - Domestic
(94.00M) (236.00M) (116.00M) (132.00M)
Income Tax - Deferred - Foreign
(28.00M) (33.00M) (13.00M) (48.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.09B 1.36B 1.37B 1.36B
Minority Interest Expense
- - - 1.00M
-
Net Income
1.09B 1.36B 1.37B 1.36B
Net Income Growth
+12.94% +24.47% +1.10% -0.95%
Net Margin Growth
+7.57% +9.08% +8.91% +8.34%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
1.09B 1.36B 1.37B 1.36B
Preferred Dividends
- - - -
-
Net Income Available to Common
1.09B 1.36B 1.37B 1.36B
EPS (Basic)
5.8156 7.3885 7.5731 7.9116
EPS (Basic) Growth
+15.23% +27.05% +2.50% +4.47%
Basic Shares Outstanding
187.60M 183.80M 181.30M 171.90M
EPS (Diluted)
5.724 7.2893 7.4864 7.8386
EPS (Diluted) Growth
+15.55% +27.35% +2.70% +4.70%
Diluted Shares Outstanding
190.60M 186.30M 183.40M 173.50M
EBITDA
2.97B 3.17B 3.38B 3.42B
EBITDA Growth
+10.63% +6.67% +6.89% +1.24%
EBITDA Margin
+20.58% +21.15% +21.96% +21.01%

Snapshot

Average Recommendation BUY Average Target Price 232.85
Number of Ratings 26 Current Quarters Estimate 3.017
FY Report Date 06 / 2026 Current Year's Estimate 12.70
Last Quarter’s Earnings 2.83 Median PE on CY Estimate N/A
Year Ago Earnings 11.92 Next Fiscal Year Estimate 14.071
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 21 21 24 24
Mean Estimate 3.02 3.19 12.70 14.07
High Estimates 3.13 3.26 12.84 14.88
Low Estimate 2.88 3.08 12.52 13.65
Coefficient of Variance 2.17 1.41 0.64 1.85

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 21 21 19
OVERWEIGHT 3 3 4
HOLD 2 2 4
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Iqvia Holdings Inc. - IQV

Date Name Shares Transaction Value
Jul 29, 2025 John G. Danhakl Director 2,614 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 29, 2025 Colleen A. Goggins Director 4,521 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 29, 2025 James A. Fasano Director 3,870 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 29, 2025 Leslie Wims Morris Director 4,589 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Iqvia Holdings Inc. in the News